z-logo
open-access-imgOpen Access
Molecular cloning of two C/EBP-related proteins that bind to the promoter and the enhancer of the α1-fetoprotein gene. Further analysis of C/EBPβ and C/EBPγ
Author(s) -
Hélène Thomassin,
D Hamel,
Daniel Bernier,
Michel Guertin,
Luc Bélanger
Publication year - 1992
Publication title -
nucleic acids research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 9.008
H-Index - 537
eISSN - 1362-4954
pISSN - 0305-1048
DOI - 10.1093/nar/20.12.3091
Subject(s) - biology , ccaat enhancer binding proteins , microbiology and biotechnology , gene expression , gene , enhancer , leucine zipper , complementary dna , regulation of gene expression , transcription factor , dna binding protein , genetics
In an attempt to identify proteins that may regulate alpha 1-fetoprotein (AFP) gene expression, we screened a cDNA expression library from neonatal rat liver with two essential cis-elements of the AFP promoter and enhancer. We isolated two cDNAs which were found to correspond to leucine zipper proteins of the CC-AAT/enhancer binding protein (C/EBP) family: C/EBP beta and C/EBP gamma. The three related proteins C/EBP alpha, beta and gamma bind with indistinguishable specificity to multiple DNA sites in the promoter and the enhancer of the AFP gene. In addition, C/EBP beta and C/EBP gamma readily heterodimerize with each other as well as with C/EBP alpha. The mRNAs coding for C/EBP beta and C/EBP gamma are expressed in a wider variety of rat tissues than C/EBP alpha mRNA, including yolk sac and fetal liver. The steady-state levels of C/EBP alpha, beta and gamma mRNAs increase during liver development, in parallel with their respective gene transcriptional rates. The high levels of C/EBP beta and gamma mRNAs in rat yolk sac and fetal liver, where C/EBP alpha is poorly expressed, suggest that C/EBP beta and/or gamma could be preponderant or early regulators of the AFP gene in these tissues.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here